Daxocox (enflicoxib) has been granted a perioperative licence for use in dogs in the UK, giving veterinary teams another licensed option for managing pain and inflammation associated with orthopaedic and soft tissue surgery.

Daxocox is a COX2 selective NSAID administered orally, with a dosing interval of seven days.

When given preoperatively, its weekly duration of action means postoperative analgesia is already in place, with the NSAID being active throughout and following the surgery.

Colin Capner, Animalcare Senior Technical Vet, said: "Administering analgesia ahead of surgery can be an important part of perioperative planning.

"This licence extension enables Daxocox to be used pre-operatively with the confidence that the NSAID contribution to analgesia is available even during surgical preparation (often neglected) in suitable patients.

"That continuity of analgesia can also provide reassurance beyond discharge, supporting a smoother transition from practice to home.

"For veterinary teams, knowing analgesic cover remains in place may help provide additional confidence when patients leave the clinic.

"For owners, it may help reduce concerns around managing a dog recovering from surgery, particularly where discomfort could affect behaviour, mobility or appetite during the first few days at home."

Full prescribing information is available in the GB/NI Summary of Product Characteristics.

www.animalcare.co.uk